CA3221710A1 - Subcutaneous formulation and methods for treating edema refractory to oral diuretics - Google Patents

Subcutaneous formulation and methods for treating edema refractory to oral diuretics Download PDF

Info

Publication number
CA3221710A1
CA3221710A1 CA3221710A CA3221710A CA3221710A1 CA 3221710 A1 CA3221710 A1 CA 3221710A1 CA 3221710 A CA3221710 A CA 3221710A CA 3221710 A CA3221710 A CA 3221710A CA 3221710 A1 CA3221710 A1 CA 3221710A1
Authority
CA
Canada
Prior art keywords
bumetanide
pharmaceutical composition
subject
solution
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3221710A
Other languages
English (en)
French (fr)
Inventor
Balasingam Radhakrishnan
Ben ESQUE
Wei Lin
Andrew Xian Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESQ Pharmaceuticals LLC
Original Assignee
RESQ Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RESQ Pharmaceuticals LLC filed Critical RESQ Pharmaceuticals LLC
Publication of CA3221710A1 publication Critical patent/CA3221710A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3221710A 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics Pending CA3221710A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208863P 2021-06-09 2021-06-09
US63/208,863 2021-06-09
PCT/US2022/032862 WO2022261344A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Publications (1)

Publication Number Publication Date
CA3221710A1 true CA3221710A1 (en) 2022-12-15

Family

ID=84425561

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3221710A Pending CA3221710A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Country Status (10)

Country Link
US (1) US20240285566A1 (https=)
EP (1) EP4351554A4 (https=)
JP (1) JP2024520788A (https=)
KR (1) KR20240042402A (https=)
CN (1) CN117915905A (https=)
AU (1) AU2022289724A1 (https=)
BR (1) BR112023025880A2 (https=)
CA (1) CA3221710A1 (https=)
IL (1) IL309160A (https=)
WO (1) WO2022261344A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7906555B2 (en) * 2006-10-26 2011-03-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
US20210163406A1 (en) * 2018-04-06 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
IL293429A (en) * 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Also Published As

Publication number Publication date
BR112023025880A2 (pt) 2024-02-27
IL309160A (en) 2024-02-01
KR20240042402A (ko) 2024-04-02
WO2022261344A1 (en) 2022-12-15
EP4351554A4 (en) 2025-05-07
AU2022289724A1 (en) 2024-01-18
JP2024520788A (ja) 2024-05-24
US20240285566A1 (en) 2024-08-29
EP4351554A1 (en) 2024-04-17
CN117915905A (zh) 2024-04-19
WO2022261344A8 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US12558330B2 (en) Methods and compositions for treating edema refractory to oral diuretics
JP7048576B2 (ja) 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
TWI815796B (zh) 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法
EP2849792B1 (en) Liquid formulation
US20120040970A1 (en) Intranasal delivery system for dantrolene
US20240285566A1 (en) Subcutaneous formulation and methods for treating edema refractory to oral diuretics
EP2632430A1 (en) Nasal compositions of vitamin b12
CN101856329A (zh) 苯甲酸利扎曲普坦口腔喷雾剂
EP4370093B1 (en) Aqueous bumetanide-containing liquid
Louaguenouni et al. Robust micelles formulation to improve systemic corticosteroid therapy in sepsis in multiple healthcare systems
WO2022217029A1 (en) Compositions and methods for delivering pharmaceutical agents
US10201552B2 (en) Method of increasing the bioavailability of an HIV drug
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
HK40080175A (en) Methods and compositions for treating edema refractory to oral diuretics
CN119300828A (zh) 尼莫地平肠胃外给药
HK1208372B (en) Liquid formulation

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251124

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260309